Table 3.
Multivariate analyses for metabolic syndrome-related disease by each stage of VFA and BMI
| N = 352 | Hypertension (n = 113) | Diabetes (n = 29) | Dyslipidemia (n = 130) | Mean IMT | PS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | Lower CI | Upper CI | p value | OR | Lower CI | Upper CI | p value | OR | Lower CI | Upper CI | p value | Average (SD) | Average (SD) | |
| BMI stage | ||||||||||||||
| BMI-1 (n = 37) | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 0.67 (0.12) | 0.00 (0.00) | ||||||
| BMI-2 (n = 236) | 0.86 | 0.36 | 2.20 | 0.748 | 1.94 | 0.34 | 36.69 | 0.505 | 2.11 | 0.92 | 5.36 | 0.080 | 0.69 (0.17) | 0.20 (0.05) |
| BMI-3 (n = 79) | 4.28 | 1.63 | 12.00 | 0.003 | 5.56 | 0.92 | 108.02 | 0.063 | 4.97 | 1.96 | 13.67 | 0.001 | 0.72 (0.14) | 0.33 (0.17) |
| VFA stage | ||||||||||||||
| VFA-1 (n = 36) | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 0.66 (0.12) | 0.03 (0.03) | ||||||
| VFA-2 (n = 102) | 0.79 | 0.29 | 2.26 | 0.646 | 0.98 | 0.12 | 20.67 | 0.989 | 1.13 | 0.48 | 2.77 | 0.774 | 0.65 (0.12) | 0.12 (0.06) |
| VFA-3 (n = 117) | 1.06 | 0.41 | 2.98 | 0.901 | 1.60 | 0.24 | 31.48 | 0.661 | 0.95 | 0.41 | 2.30 | 0.902 | 0.70 (0.15) | 0.14 (0.08) |
| VFA-4 (n = 49) | 2.04 | 0.70 | 6.27 | 0.193 | 4.27 | 0.66 | 84.33 | 0.140 | 1.70 | 0.65 | 4.61 | 0.282 | 0.72 (0.20) | 0.07 (0.05) |
| VFA-5 (n = 48) | 4.07 | 1.36 | 13.06 | 0.012 | 6.75 | 1.07 | 132.51 | 0.041 | 3.76 | 1.38 | 10.81 | 0.009 | 0.77 (0.19) | 0.85 (0.31) |
Covariates: age, sex, current smoking (+), average daily physical active level, alcohol intake per week, biologics use, prednisolone use, methotrexate use, and DAS28-ESR
VFA-1; VFA < 25, VFA-2; 25 ≤ VFA < 50, VFA-3; 50 ≤ VFA < 75; VFA-4; 75 ≤ VFA < 100, VFA-5; VFA ≥ 100. BMI-1; BMI < 18.5, BMI-2; 18.5 ≤ BMI < 25, BMI-3; BMI ≥ 25
OR odds ratio, CI 95% confidence interval, SD standard deviation, VFA visceral fat area (cm2), BMI Body Mass Index